Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
03:38pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
05:06pm, Friday, 28'th Oct 2022 Zacks Investment Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics
04:02pm, Friday, 28'th Oct 2022 Zacks Investment Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
04:19pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
04:14pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
05:20pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
04:08pm, Monday, 17'th Oct 2022 Zacks Investment Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Puma Biotechnology: Alisertib Deal Alters My Strategy
04:13am, Monday, 26'th Sep 2022
Puma Biotechnology publicized a licensing deal for Takeda's alisertib, “a selective, small-molecule, orally administered inhibitor of aurora kinase A.” This has altered how I plan on managing my P
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
03:35pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
12:48pm, Wednesday, 21'st Sep 2022
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
04:15pm, Tuesday, 06'th Sep 2022
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present at H.C. Wainwright's Annual Conf. The presentation will be available on Puma's website beginning at 7:00 am ET on 9/12/22.
Why Puma Biotechnology Shares Dropped 17.7% This Week
10:33pm, Thursday, 01'st Sep 2022 The Motley Fool
With no good news, the stock fell with the rest of the market.
Why Puma Biotechnology Shares Dropped 17.7% This Week
06:33pm, Thursday, 01'st Sep 2022
With no good news, the stock fell with the rest of the market.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
05:17pm, Friday, 26'th Aug 2022 Zacks Investment Research
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
02:18pm, Friday, 26'th Aug 2022
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
